ArticlebioRxiv : the preprint server for biology2026
AlphaGenome Enhances Personal Gene Expression Prediction but Retains Key Limitations.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In recent years, numerous genome AI models have been developed to elucidate the relationship between DNA sequence and gene expression. However, these models have faced criticism for their limited accuracy in predicting individual-specific gene expression. AlphaGenome, the current state-of-the-art in genome AI, achieves exceptional performance across a range of sequence-based predictive tasks, but its utility for personal expression prediction has not yet been assessed. In this study, we evaluate AlphaGenome's ability to predict personal gene expression and find that it significantly outperforms its predecessor. Using GTEx data, AlphaGenome improves the prediction of expression direction over Enformer, achieving an odds ratio of 3.0. In some cases, it even reverses previously observed negative correlations into positive ones. Moreover, AlphaGenome demonstrates improved performance for genes with known nonlinear sequence-expression relationships, though it uncovers mechanisms distinct from those identified by tree-based models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.